UPDATE

CMC Biologics to make Harpoon’s cancer drugs in California, US

By Flora Southey contact

- Last updated on GMT

GettyImages/urfinguss
GettyImages/urfinguss

Related tags: Cmc biologics, Immune system

Harpoon Therapeutics has selected CMC Biologics to develop and manufacture three molecules for cancer treatments at the CDMO’s facilities in California and Washington State, US.

Harpoon said its three candidates - HPN424, HPN536, and HPN217 – were developed using its  antibody-based drug discovery platform, TriTAC technology (Tri-specific T cell Activating Construct).

TriTAC antibodies activate T cells – a subtype of a white blood cell in the adaptive immune system – to target and kill cancer cells. Harpoon said it plans to move HPN424 into Phase I clinical trials for metastatic prostate cancer next year.  

CMC Biologics said it will use its CHEF1 Expression Platform to create clinical and commercial product cell lines for the biologics.

“Our advanced CHEF1 Expression Technology will facilitate production of high levels of recombinant protein in rapid time-frames, with a focus on an accelerated process, precise outputs, and excellence in service,” ​said CMC Biologics’ CEO Gustavo Mahler.

Facilities

Chief business officer Bob Broeze told us CMC Biologics will develop the molecules at its facility in Bothell, Washington, before they are “transferred to our Berkeley, California facility for manufacturing.”

The contract development and manufacturing organisation’s (CDMO) Bothell site – located near Seattle – houses two 3,000L stainless steel bioreactor lines, two 750L bioreactors, two cell expansion suites and three single-use bioreactors.

The firm told us it does not expect to be adding any additional equipment or staff for this project.

CMC Biologics was bought by Japanese chemical firm AGC Asahi Glass in December​ last year.

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Related suppliers

Follow us

Products

View more

Webinars